For the year ending 2025-12-31, TARS had $88,822K increase in cash & cash equivalents over the period. -$22,310K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -66,418 |
| Depreciation | 855 |
| Amortization of intangible assets | 961 |
| Amortization/accretion of debt-related costs | 593 |
| Stock-based compensation | 41,720 |
| Loss on debt extinguishment | 0 |
| Non-cash lease expense | 682 |
| Net amortization/accretion on marketable securities | 5,482 |
| Realized/unrealized loss (gain) on equity investments | 0 |
| Change in fair value of equity warrants issued by licensee | 0 |
| Accounts receivable, net | 38,297 |
| Inventory | 1,751 |
| Other receivables | 754 |
| Prepaid expenses | -1,716 |
| Other non-current assets | 527 |
| Accounts payable | 6,906 |
| Accrued payroll and benefits | 1,956 |
| Other accrued liabilities | 45,389 |
| Other long-term liabilities | 0 |
| Net cash used in operating activities | -12,451 |
| Proceeds from sales and maturities of marketable securities | 361,800 |
| Purchases of marketable securities | 393,186 |
| Purchases of long-term investments | 870 |
| Intangible asset additions | 0 |
| Purchases of property and equipment | 9,859 |
| Net cash (used in) provided by investing activities | -42,115 |
| Proceeds from issuance of common stock, net of paid issuance costs-Common Stock | 134,771 |
| Proceeds from issuance of pre-funded warrants, net of paid issuance costs | 0 |
| Proceeds from exercise of stock options | 6,280 |
| Proceeds from sale of common stock under employee stock purchase plan | 2,337 |
| Proceeds from issuance of common stock, net of paid issuance costs-A2023ATMProspectus | 0 |
| Proceeds from long-term debt | 0 |
| Payment of debt issuance costs | 0 |
| Payments for debt extinguishment | 0 |
| Net cash provided by financing activities | 143,388 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 88,822 |
| Cash, cash equivalents and restricted cash at beginning of period | 97,381 |
| Cash, cash equivalents and restricted cash at end of period | 186,203 |
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)